Skip to main content
Log in

Cost effectiveness of RSV intervention in GAVI-eligible countries

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Reference

  • Li X, et al. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Medicine : 6 Apr 2020. Available from: URL: https://doi.org/10.1186/s12916-020-01537-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cost effectiveness of RSV intervention in GAVI-eligible countries. PharmacoEcon Outcomes News 851, 13 (2020). https://doi.org/10.1007/s40274-020-6736-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6736-2

Navigation